CS Group, trading as CS Diagnostics Corp. on the OTCQB market under the symbol CSDX, has appointed Shah Teelani & Associates as its PCAOB-registered auditor to consolidate all 2025 financial statements for the company and its subsidiaries. This strategic decision represents a significant step in the company's evolution as it expands operations internationally across the United States, GCC region, and Europe.
The Dubai-based audit firm will oversee the consolidation and audit of financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. Management stated that appointing a PCAOB-registered audit firm aligns the Group's financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. This move reflects the company's commitment to strengthening financial governance, regulatory compliance, and transparency.
The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence as the company advances its international expansion strategy. The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. According to Mohammad Essayed, Group Chief Financial Officer, "Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group's evolution as a publicly traded company. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance."
The company continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap. CS Diagnostics Corp. is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The company's portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy.
This appointment comes as the company progresses through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap. For further information about the company and its operations, visit https://group-csd.com/.
